The FDA has approved lerodalcibep-liga, a third-generation injectable PCSK9 inhibitor, for lowering LDL cholesterol in adults ...

The FDA has approved lerodalcibep-liga, a third-generation injectable PCSK9 inhibitor, to reduce LDL cholesterol in adults ...

LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients ...

FDA has announced the approval of LIB Therapeutics’ Lerochol (lerodalcibep-liga) for subcutaneous (SC) use as an adjunct to ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol goals, today announced the U.S. Food and Drug ...

Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...

As of Friday, December 19, BioMarin Pharmaceutical Inc.’s BMRN share price has surged by 14.13%, which has investors questioning if this is right time to sell.

RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw)SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1 ...

Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd , has entered into two strategic agreements with privately held Hasten ...